As we all wait for the replication validity to the pilot study results(tic-toc), an hope an equal or even better efficacy is shown on this larger population of animal studies we should not lose sight of the genetech proposed prospect early 2016.
Not only was this licensing prospect late 2014 what first caught my interest, furthermore the in house results are out soon. Although the focus this year has been on the newer developments of pyc's oncology progress, their superbug progress of older appears to be closer than before, luck to all holders.
As we all wait for the replication validity to the pilot study...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13987 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 1380 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |